Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_0150 |
| Primary information | |
|---|---|
| B3PDB ID | b3pdb_0150 |
| Peptide Name | MMP-2200 |
| PEPTIDE SEQUENCE (1-letter) | Y-D-TGFLS(β-O-Glc)-CONH2 |
| PEPTIDE SEQUENCE (3-letter) | Tyr-D-Thr-Gly-Phe-Leu-Ser(β-O-Glc)-CONH2 |
| N-terminal modification | NA |
| C-terminal modification | NA |
| Chemical modification | Glycosylated serine residue |
| Peptide Length | 6 |
| Conformation | Linear |
| Peptide Nature | NA |
| Source/Origin of peptide | Chemically synthesized |
| SMILES | NA |
| Cell Line | NA |
| In vitro CONCENTRATION | NA |
| In vitro METHOD | NA |
| In vitro RESULT | NA |
| ANIMAL MODEL | Adult Sprague-Dawley rats |
| In vivo CONCENTRATION | 10mg/Kg |
| In vivo MODE OF DELIVERY | Intraperitoneal |
| In vivo METHOD | Microdialysis analysis and LCMS analysis |
| In vivo RESULT | Significant amount of peptide crosses blood brain barrier after 12 minute and remain stable up to 80 |
| ACTION | Shows potent analgesic behaviour |
| TRANSPORT TYPE | NA |
| SUBCELLULAR LOCALISATION | NA |
| COMBINATION | NA |
| PHYSICAL CONDITION | Parkinson |
| RESPONSE | Stability/half life |
| RESULT | 80 minute |
| LABEL | NA |
| PMID | 23127847 |